Generated Narrative: Citation 179613

url: Citation 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

identifier: FEvIR Object Identifier/179613, https://pubmed.ncbi.nlm.nih.gov/27308831, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.27

version: 2.0.0-ballot

title: 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

status: Active

date: 2024-11-21 14:09:14+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2017-07-26

lastReviewDate: 2024-03-27

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of epublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2016-04-01

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2016-06-02

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2016-06-17 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2016-06-17 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2017-07-27 06:00:00+0000

statusDate

activity: PubMed Pubstatus of PMC release

period: ?? --> 2016-06-16

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/27308831, https://www.ncbi.nlm.nih.gov/pmc//PMC4911003, https://doi.org/10.1371/journal.pone.0157660, pii/PONE-D-16-10077

Titles

-	Type	Language	Text
*	Primary title	English	Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

Abstracts

-

Text

*

OBJECTIVE: Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC). METHODS: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI). RESULTS: The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p<0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p<0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p<0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade ≥3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue. CONCLUSION: The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients.

relatesTo

type: cites

citation:

http://clinicaltrials.gov/ct2/show/NCT00514540.

relatesTo

type: cites

classifier: Journal Article

citation:

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60(2):279–90. Epub 2011/05/20. doi: S0302-2838(11)00477-5 [pii] 10.1016/j.eururo.2011.04.038 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/21592649/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/21592649

relatesTo

type: cites

classifier: Journal Article

citation:

Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. International braz j urol: official journal of the Brazilian Society of Urology. 2012;38(6):717–27. Epub 2013/01/11. .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23302410/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23302410

relatesTo

type: cites

classifier: Journal Article

citation:

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605. Epub 2007/04/04. doi: JCO.2006.10.1949 [pii] 10.1200/JCO.2006.10.1949 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/17404365/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/17404365

relatesTo

type: cites

classifier: Journal Article

citation:

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65(2):467–79. Epub 2013/12/11. 10.1016/j.eururo.2013.11.002 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24321502/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24321502

relatesTo

type: cites

classifier: Journal Article

citation:

Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. Epub 2015/07/25. 10.1093/annonc/mdv222 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26205393/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26205393

relatesTo

type: cites

classifier: Journal Article

citation:

Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004;11(2):103–9. Epub 2004/01/07. .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/14706014/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/14706014

relatesTo

type: cites

classifier: Journal Article

citation:

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004;351(15):1513–20. Epub 2004/10/08. 10.1056/NEJMoa041318 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/15470214/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15470214

relatesTo

type: cites

classifier: Journal Article

citation:

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502–12. Epub 2004/10/08. 10.1056/NEJMoa040720 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/15470213/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15470213

relatesTo

type: cites

classifier: Journal Article

citation:

Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–7. Epub 2015/05/24. 10.1093/annonc/mdv245

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26002607/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26002607

relatesTo

type: cites

classifier: Journal Article

citation:

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149–58. Epub 2013/01/12. 10.1016/s1470-2045(12)70560-0 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23306100/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23306100

relatesTo

type: cites

citation:

Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naive metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial. 2015 Genitourinary Cancers Symposium Abstract 140 Presented February 26, 2015.

relatesTo

type: cites

classifier: Journal Article

citation:

Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European urology. 2015. Epub 2015/11/28. 10.1016/j.eururo.2015.11.005 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26610858/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26610858

relatesTo

type: cites

classifier: Journal Article

citation:

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737–46. Epub 2015/08/06. 10.1056/NEJMoa1503747

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26244877/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26244877

relatesTo

type: cites

citation:

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s, 2014. (suppl; abstr LBA2).

relatesTo

type: cites

classifier: Journal Article

citation:

Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–91. Epub 1994/11/12. .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/7718048/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/7718048

relatesTo

type: cites

citation:

Clarke M, Oxman AD, (Editors). Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software.2000.

relatesTo

type: cites

classifier: Journal Article

citation:

Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999;117(3):138–9. Epub 1999/10/08. doi: S1516-3180(99)11700311 [pii]. .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/10511734/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/10511734

relatesTo

type: cites

classifier: Journal Article

citation:

Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London: BMJ Books; 2001.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/11440947/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/11440947

relatesTo

type: cites

citation:

Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

relatesTo

type: cites

classifier: Journal Article

citation:

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. Epub 1999/01/28. [pii]. .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9921604/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/9921604

relatesTo

type: cites

classifier: Journal Article

citation:

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. Epub 2003/09/06. 10.1136/bmj.327.7414.557 327/7414/557 [pii].

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/12958120/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/12958120

relatesTo

type: cites

classifier: Journal Article

citation:

Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010;30(4):229–41. Epub 2010/03/17. doi: 2 [pii] 10.2165/11532260-000000000-00000 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/20225906/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/20225906

relatesTo

type: cites

citation:

Deeks JJ, Higgins JP, Altman DG. Analysing and presenting results In: Higgins JP, G S editor. Cochrane Handbook for Systematic Reviews of In- terventions (ed 426 [updated September 2006]). Chichester, United Kingdom: John Wiley & Sons Ltd; 2006.

relatesTo

type: cites

classifier: Journal Article

citation:

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. Epub 1986/09/01. doi: 0197-2456(86)90046-2 [pii]. .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/3802833/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/3802833

relatesTo

type: cites

classifier: Journal Article

citation:

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Epub 1997/10/06.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9310563/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/9310563

relatesTo

type: cites

classifier: Journal Article

citation:

McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712–20. Epub 1997/05/01. .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9139558/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/9139558

relatesTo

type: cites

classifier: Journal Article

citation:

Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading. BMJ. 1999;318(7197):1548–51. Epub 1999/06/04.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/10356018/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/10356018

relatesTo

type: cites

classifier: Journal Article

citation:

Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3 Epub 2002/02/28.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/11860606/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/11860606

relatesTo

type: cites

classifier: Journal Article

citation:

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94. Epub 2009/07/23. doi: 0000605-200908180-00136 [pii].

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/19622512/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/19622512

relatesTo

type: cites

classifier: Journal Article

citation:

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet Oncology. 2015;16(7):787–94. Epub 2015/06/02. 10.1016/s1470-2045(15)00011-x .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26028518/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26028518

relatesTo

type: cites

classifier: Journal Article

citation:

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81(3):611–6. Epub 2013/03/05. 10.1016/j.urology.2012.12.025 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23452809/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23452809

relatesTo

type: cites

classifier: Journal Article

citation:

Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. Journal of hematology & oncology. 2014;7:20 Epub 2014/03/07. 10.1186/1756-8722-7-20

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24598155/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24598155

relatesTo

type: cites

classifier: Journal Article

citation:

Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. European urology. 2012;62(2):213–9. Epub 2012/04/17. 10.1016/j.eururo.2012.03.053 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/22502942/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22502942

relatesTo

type: cites

classifier: Journal Article

citation:

Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (London, England). 2011;378(9809):2104–11. Epub 2011/11/08. 10.1016/s0140-6736(11)61095-7

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/22056152/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/22056152

relatesTo

type: cites

classifier: Journal Article

citation:

Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (London, England). 2009;373(9660):301–8. Epub 2008/12/19. 10.1016/s0140-6736(08)61815-2 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/19091394/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/19091394

relatesTo

type: cites

classifier: Journal Article

citation:

Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer chemotherapy and pharmacology. 2013;71(6):1629–34. Epub 2013/04/23. 10.1007/s00280-013-2163-4 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23604530/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23604530

relatesTo

type: cites

classifier: Journal Article

citation:

Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol. 2015;33(8):337.e1–6. Epub 2015/06/21. 10.1016/j.urolonc.2015.05.012 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26092557/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26092557

relatesTo

type: cites

classifier: Journal Article

citation:

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology. 2015;67(6):1028–38. Epub 2014/10/11. 10.1016/j.eururo.2014.09.032 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25301760/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25301760

relatesTo

type: cites

citation:

James ND, Sydes MR, Mason M, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 33, 2015. (suppl; abstr 5001).

relatesTo

type: cites

citation:

Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, et al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 34, 2016. (suppl 2S; abstr 286).

relatesTo

type: cites

classifier: Journal Article

citation:

Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2008;88(1):1–9. Epub 2008/05/27. doi: S0167-8140(08)00233-8 [pii] 10.1016/j.radonc.2008.04.013 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/18501455/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/18501455

relatesTo

type: cites

classifier: Journal Article

citation:

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–604. Epub 2015/06/05. 10.1093/annonc/mdv257

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26041764/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26041764

relatesTo

type: cites

classifier: Journal Article

citation:

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 2013;14(2):117–24. Epub 2013/01/09. 10.1016/s1470-2045(12)70537-5 .

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23294853/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23294853

relatesTo

type: cites

citation:

Kellokumpu-Lehtinen PL, Harmenberg U, Hervonen P, Joensuu TK, McDermott RS, Ginman C, et al. Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. J Clin Oncol 32, 2014. (suppl 4; abstr 23).

relatesTo

type: cites

citation:

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

relatesTo

type: cites

citation:

Liaw BC, Oh WK. Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer? The American Journal of Hematology/oncology 2015; 11(9):17–20

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1932-6203, ISOAbbreviation/PLoS One, ISSN Linking/1932-6203, Medline Title Abbreviation/PLoS One, NLM Unique ID/101285081

title: PloS one

publisherLocation: United States

citedMedium: Internet

volume: 11

issue: 6

articleDate: 2016

publicationDateText: 2016

language: English

pageString: e0157660

publicationForm

citedMedium: Internet without issue

articleDate: 2016-06-16

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/27308831/

webLocation

classifier: DOI Based

url: https://doi.org/10.1371/journal.pone.0157660

classification

type: Publishing Model

classifier: Electronic-eCollection

classification

type: Chemical

classifier: Androgen Antagonists, Antineoplastic Agents, Taxoids, Tubulin Modulators, Docetaxel

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Journal Article, Meta-Analysis, Review, Systematic Review

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Botrel TE

forenameInitials: TE

affiliation:

• Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.
• Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.

entry

contributor: Clark O

forenameInitials: O

affiliation:

• Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.
• Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.

entry

contributor: Lima Pompeo AC

forenameInitials: AC

affiliation: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.

entry

contributor: Horta Bretas FF

forenameInitials: FF

affiliation: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.

entry

contributor: Sadi MV

forenameInitials: MV

affiliation: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.

entry

contributor: Ferreira U

forenameInitials: U

affiliation: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.

entry

contributor: Borges Dos Reis R

forenameInitials: R

affiliation: Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.

Generated Narrative: Practitioner #contributor0

name: Tobias Engel Ayer Botrel

Generated Narrative: Practitioner #contributor1

name: Otávio Clark

Generated Narrative: Practitioner #contributor2

name: Antônio Carlos Lima Pompeo

Generated Narrative: Practitioner #contributor3

name: Francisco Flávio Horta Bretas

Generated Narrative: Practitioner #contributor4

name: Marcus Vinicius Sadi

Generated Narrative: Practitioner #contributor5

name: Ubirajara Ferreira

Generated Narrative: Practitioner #contributor6

name: Rodolfo Borges Dos Reis

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Androgen Antagonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Antineoplastic Agents

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Antineoplastic Combined Chemotherapy Protocols

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Docetaxel

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Lymphatic Metastasis

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Patient Safety

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Prostatic Neoplasms

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	Yes

component

type: qualifier

classifier: mortality

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: pathology

Components

-	Type	Classifier
*	is Major topic	No

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Randomized Controlled Trials as Topic

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Survival Analysis

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Taxoids

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Treatment Outcome

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

informationType: Classifier

type: components (if present) include qualifier codings

classifier: Tubulin Modulators

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	Yes